Susan Ide

Susan Ide

Susan’s Company

Novartis

Website: http://www.novartis.com

Twitter: @novartis

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a ... More » Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in each of these areas. In 2008, the GroupÂ’s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number two in sales (46.806 billion US$) among the world-wide industry in 2010. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include cyclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta, in partnership with AstraZeneca which also divested its agrochemical business. Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). [ CrunchBase ]

eFFECTOR Therapeutics Raises $45 Million in Series A Financing

" In addition to Dr. Lasky, eFFECTOR has named the following Board members: Ken Haas, Executive Partner at Abingworth; Markus Goebel, M.D., Ph.D., Managing Director at Novartis Venture Funds; and Simeon George, M.D., Partner at SR One. eFFECTOR also announced the appointment of Carol ...

Markus Goebel

Mentioned in this article:
Markus Goebel

Trials in Esophageal Ca, HCC Fall Short

Novartis - Note that these studies were published as abstracts and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal. SAN FRANCISCO -- Patients with esophageal cancer derived no survival benefit with the addition of ...

Andrew Zhu

Mentioned in this article:
Andrew Zhu

The World Today - India court rules against cancer drug patent 02/04/2013

Novartis - Its managing director in India, Ranjit Shahani, says poor people will be the losers in this decision. RANJIT SHAHANI: The ruling is a set-back for patients. The primary concern that we have of course is India's non-recognition of intellectual property rights, which sustain research and ...

Ranjit Shahani

Mentioned in this article:
Ranjit Shahani

NetConsumo: Researchers look to improve understanding of complex brain

Novartis - “We have already identified a lot of gaps in knowledge about treatments of brain diseases,” said Gordon Francis, head of the NeuroInflammation Clinical Science Unit within the NeuroScience Franchise at the Swiss pharmaceutical company Novartis. RPDC - Revista Portuguesa de Direito do ...

Gordon Francis

Mentioned in this article:
Gordon Francis

U.S. files second lawsuit accusing Novartis of kickbacks - Yahoo! News

Novartis spokeswoman Julie Masow said the company disputes the claims in both lawsuits and will defend itself. Its Novartis Pharmaceuticals unit is based in East Hanover, New Jersey. The original lawsuit over alleged kickbacks to doctors had been filed by Oswald Bilotta, a former ...

Julie Masow

Mentioned in this article:
Julie Masow

Novartis loses Indian patent fight on cancer drug | Egypt Independent

" "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options," said Ranjit Shahani, managing director of Novartis India. Shares of Novartis India, the local unit of the Basel-headquartered group, were down 4.31 percent at ...

Ranjit Shahani

Mentioned in this article:
Ranjit Shahani

Drug maker Novartis loses India patent battle - seattlepi.com

"We brought this case because we strongly believe patents safeguard innovation and encourage medical progress," said Ranjit Shahani, Vice Chairman and Managing Director, Novartis India. The ruling "will hinder medical progress for diseases without effective treatment options," he said. ...

Drug maker Novartis loses India patent battle - Houston Chronicle

Ranjit Shahani, the vice chairman and managing director of Novartis India, said the ruling "will hinder medical progress for diseases without effective treatment options. " He said the court's decision made India an even less attractive country for major investments by international ...

Pharma: Generics and enforcement make an impact | Business Standard

Ranjit Shahani, vice-chairman and managing director, Novartis India, said, "We hope we have a progressive and stable FDI policy, an ecosystem which encourages innovation and some sensibility to move the debate from a nationalistic to a healthcare one. " Some are hopeful and expect growth ...

Join Newsle to find out when Susan Ide makes the news.

As a Newsle member, you’ll be able to:

  • Get alerts on Susan Ide
  • See news articles & blog posts about Susan Ide
  • Follow your friends & colleagues in the news
This profile only includes publicly available information. Questions or comments? Contact Us
Freebase CC-BY
Data from Freebase, licensed under CC-BY
Source: CrunchBase
Data from Wikipedia, licensed under the GFDL